ALERT!

This site is not optimized for Internet Explorer 8 (or older).

Please upgrade to a newer version of Internet Explorer or use an alternate browser such as Chrome or Firefox.

TAVR vs. Surgery: A New Look at 1-Year Outcomes Among Moderate-Risk Patients with Severe, Symptomatic AS

Thursday, May 19, 2022

Submitted by

Source

Author(s)

Michael Walter

Transcatheter aortic valve replacement (TAVR) is not inferior to surgical aortic valve replacement (SAVR) when it comes to all-cause mortality after one year. This is among moderate-risk patients with severe, symptomatic aortic stenosis (AS). According to a new analysis published in JAMA,  a close comparison revealed that each treatment option is associated with certain benefits over the other.

Comments

Add comment

Log in or register to post comments